The Global Restless Legs Syndrome Treatment Market is driven by increasing patient awareness
Restless Legs Syndrome (RLS) is a sensorimotor disorder characterized by unpleasant or uncomfortable sensations in the legs and an irresistible urge to move them. The exact cause of RLS is not fully understood, however it is believed to be related to abnormalities in iron levels, and dopamine metabolism in the brain. There is currently no permanent cure for RLS, but treatments help relieve symptoms and improve quality of life. Prescription drugs are the mainstay of treatment and include dopaminergic drugs such as pramipexole, ropinirole and cabergoline and alpha-2-delta ligands such as pregabalin. These prescription medications work to regulate dopamine and reduce symptoms. Non-drug treatments include physical therapy, lifestyle changes, and massage. The global RLS treatment market is primarily driven by the growing prevalence of RLS disorder and increasing awareness about its diagnosis and treatment options.
The restless legs syndrome treatment market is estimated to be valued at USD 2.5 Bn in 2024 and is expected to reach USD 2.64 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.
Key players operating in the Restless Legs Syndrome treatment market are GlaxoSmithKline plc, Ligand Pharmaceuticals, Jazz Pharmaceuticals, Hisamitsu Pharmaceutical Co., Inc., and Sun Pharmaceutical Industries Ltd.
The growing demand for safe and effective Restless Legs Syndrome Treatment Market options is expected to boost market growth over the forecast period. The social and economic burden of untreated RLS will further augment demand.
Get more insights on -Restless Legs Syndrome Treatment Market
Get this Report in Japanese Language: レストレスレッグス症候群治療市場
Get this Report in Korean Language: 하지불안증후군 치료 시장
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian